Compare GILT & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GILT | AMPH |
|---|---|---|
| Founded | 1987 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.0M | 885.4M |
| IPO Year | 1997 | 2005 |
| Metric | GILT | AMPH |
|---|---|---|
| Price | $9.81 | $23.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $19.00 | ★ $28.38 |
| AVG Volume (30 Days) | ★ 478.8K | 343.0K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.81 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | $15.06 | $6.90 |
| Revenue Next Year | $11.72 | $4.64 |
| P/E Ratio | $42.82 | ★ $29.41 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.37 | $16.65 |
| 52 Week High | $20.99 | $29.52 |
| Indicator | GILT | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 39.87 | 63.17 |
| Support Level | $9.37 | $18.36 |
| Resistance Level | $10.47 | $24.35 |
| Average True Range (ATR) | 0.37 | 0.71 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 30.91 | 73.69 |
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.